Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28872731 | 0.79 | PTGS1 (0.39) | PTGS1CYP2C9AKR1C3PARP1PARP15 | |
| SCHEMBL5710629 | 0.78 | PTGS1 (0.37) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL7778372 | 0.78 | PTGS1 (0.37) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL28227710 | 0.78 | PTGS1 (0.37) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL15362103 | 0.76 | PTGS1 (0.35) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL560356 | 0.70 | ALDH1A1 (0.43) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL11801788 | 0.70 | ALDH1A1 (0.43) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL9723870 | 0.69 | — | — | |
| SCHEMBL9723868 | 0.69 | — | — | |
| SCHEMBL4771428 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337664-A1 | FRUIT FLY CONTROL | MACQUARIE UNIVERSITY (AU) | 2023-10-26 | — | — | US | claimed |
| EP-2612657-B1 | ORODISPERSIBLE TABLET | KYOWA KIRIN CO LTD (JP) | 2023-08-09 | — | — | EP | claimed |
| US-20260041699-A1 | FOSPROPOFOL FORMULATIONS | EPALEX CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| US-12397006-B2 | Fospropofol formulations | EPALEX CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20230337664-A1 | FRUIT FLY CONTROL | MACQUARIE UNIVERSITY (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| EP-2612657-B1 | ORODISPERSIBLE TABLET | KYOWA KIRIN CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-20230172952-A1 | Fospropofol Salts, Methods And Compositions | EPALEX CORP (US) | 2023-06-08 | — | — | US | disclosed |
| US-11628178-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| EP-0643981-B1 | A matrix for iontophoreses | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6322550-B2 | Method for transdermal administration of GP IIb/IIIa antagonist | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-1138345-A2 | A matrix for iontophoreses | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-20010018568-A1 | METHOD FOR TRANSDERMAL ADMINISTRATION OF GP IIB/IIIA ANTAGONIST | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-08-30 | — | — | US | disclosed |
| EP-0950407-A1 | Method for transdermal administration of GP IIb/IIIa antagonist | Takeda Chemical Industries, Ltd. (JP) | 1999-10-20 | — | — | EP | disclosed |
| EP-0575974-B1 | Use of 24,25-dihydroxyvitamin D3 for the manufacture of a medicament for the treatment of rickets | KUREHA CHEMICAL IND CO LTD (JP) | 1997-01-08 | — | — | EP | disclosed |
| US-5508274-A | SIDE EFFECT REDUCTION | KUREHA CHEMICAL INDUSTRY COMPANY, LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0643981-A1 | A matrix for iontophoreses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0575974-A1 | Use of 24,25-dihydroxyvitamin D3 for the manufacture of a medicament for the treatment of rickets | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628178-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | PTGS1 1812/4885CYP2C9 69/4885AKR1C3 1791/4885 |
| US-20230172952-A1 | Fospropofol Salts, Methods And Compositions | FOS, FOSB, SCN5A | PTGS1 2265/4885CYP2C9 352/4885AKR1C3 1897/4885 |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | PTGS1 1812/4885CYP2C9 69/4885AKR1C3 1791/4885 |
| US-20230337664-A1 | FRUIT FLY CONTROL | NONO, HTR1D, TAS1R1 | PTGS1 2832/4885CYP2C9 813/4885AKR1C3 3409/4885 |
| US-20260041699-A1 | FOSPROPOFOL FORMULATIONS | FOS, PSEN1, FDPS | PTGS1 2352/4885CYP2C9 182/4885AKR1C3 604/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | PTGS1 1812/4885CYP2C9 69/4885AKR1C3 1791/4885 |
| US-12397006-B2 | Fospropofol formulations | FOS, PFAS, FOSB | PTGS1 4040/4885CYP2C9 93/4885AKR1C3 1328/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | PTGS1 1812/4885CYP2C9 69/4885AKR1C3 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.